Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

10.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.5K
Probability Laws01:49

Probability Laws

43.9K
Overview
43.9K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

3.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.6K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.5K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.5K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.5K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

786
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
786

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the Xpert Carba-R NxG Assay for Detection of Carbapenemase Genes in a Global Challenge Set of Pseudomonas aeruginosa Isolates.

Journal of clinical microbiology·2020
Same author

Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β-lactamase-producing Enterobacterales in the neutropenic murine thigh infection model.

The Journal of antimicrobial chemotherapy·2020
Same author

Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms.

Current opinion in infectious diseases·2020
Same author

Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo-β-Lactamase-Producing <i>Enterobacteriaceae</i>.

Journal of clinical microbiology·2020
Same author

Bactericidal In Vitro Activity of a Tissue-Achievable Concentration of Cefazolin against Methicillin-Resistant <i>Staphylococcus aureus</i>.

Surgical infections·2020
Same author

In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria.

The Journal of antimicrobial chemotherapy·2020

Related Experiment Video

Updated: Jan 20, 2026

The Use of a &#946;-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions
08:06

The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions

Published on: February 1, 2018

9.5K

Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target

James M Kidd1, Gary E Stein2, David P Nicolau1

  • 1Center for Anti-Infective Research and Development, Hartford Hospital, Harford, Connecticut, USA.

Journal of Clinical Pharmacology
|August 20, 2019
PubMed
Summary

Monte Carlo simulations for beta-lactam/beta-lactamase inhibitor combinations require improved methods. Accounting for pharmacokinetic parameter correlations and covariates enhances probability of target attainment predictions for ceftazidime/avibactam.

Keywords:
infectious diseases (INF)modeling and simulationpharmacokinetics and drug metabolismpharmacometricspopulation pharmacokinetics

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K
Near Infrared Optical Projection Tomography for Assessments of &#946;-cell Mass Distribution in Diabetes Research
15:18

Near Infrared Optical Projection Tomography for Assessments of β-cell Mass Distribution in Diabetes Research

Published on: January 12, 2013

16.9K

Related Experiment Videos

Last Updated: Jan 20, 2026

The Use of a &#946;-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions
08:06

The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions

Published on: February 1, 2018

9.5K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K
Near Infrared Optical Projection Tomography for Assessments of &#946;-cell Mass Distribution in Diabetes Research
15:18

Near Infrared Optical Projection Tomography for Assessments of β-cell Mass Distribution in Diabetes Research

Published on: January 12, 2013

16.9K

Area of Science:

  • Pharmacology
  • Pharmacokinetics
  • Computational Biology

Background:

  • Monte Carlo simulations (MCSs) are crucial for predicting pharmacodynamic target attainment (PTA) in antibiotic development.
  • Linking simulated concentration profiles for beta-lactam (BL) and beta-lactamase inhibitor (BLI) components in BL-BLICs remains methodologically underdeveloped.
  • Previous pharmacokinetic models for ceftazidime/avibactam in critically ill patients provide a basis for simulation.

Purpose of the Study:

  • To evaluate different methods for coupling BL and BLI components in MCSs for ceftazidime/avibactam.
  • To compare the impact of increasing complexity in coupling methods on PTA predictions.
  • To guide future MCS analyses for BL-BLIC combinations.

Main Methods:

  • Four 5000-patient MCSs were performed using a ceftazidime/avibactam pharmacokinetic model.
  • Methods ranged from ignoring covariates and correlations (Method A) to progressively incorporating parameter correlations and creatinine clearance (CRCL) (Methods B, C, D).
  • PTA was compared for ceftazidime and avibactam targets at various MICs (1-128 mg/L).

Main Results:

  • Method D, which included pharmacokinetic parameter correlation within each drug, CRCL, and between drugs, best recapitulated observed patient pharmacokinetic relationships.
  • Ceftazidime/avibactam PTA at MIC 8 mg/L ranged from 92.4% to 98.3%, and at 16 mg/L ranged from 80.2% to 88.4%.
  • PTA estimates were similar across methods B, C, and D, but lower with Method A; inclusion of correlations and covariates resulted in higher PTA.

Conclusions:

  • Incorporating covariate relationships and parameter correlations between BL and BLI components improves MCS accuracy for ceftazidime/avibactam.
  • More sophisticated coupling methods reduce discordant pharmacokinetic parameters, leading to higher PTA.
  • These findings underscore the importance of advanced simulation methodologies for BL-BLIC development.